DE 096

Drug Profile

DE 096

Alternative Names: DE-096

Latest Information Update: 25 Mar 2009

Price : $50

At a glance

  • Originator Santen Pharmaceutical
  • Class Small molecules
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic macular oedema; Rheumatoid arthritis

Most Recent Events

  • 10 May 2005 Phase-II clinical trials in Rheumatoid arthritis in Japan (PO)
  • 10 May 2005 Phase-II clinical trials in Diabetic macular oedema in Japan (PO)
  • 31 Dec 2003 Phase-I clinical trials in Rheumatoid arthritis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top